CERO THERAPEUTICS HOLDINGS, INC. (CERO): Nasdaq/NYSE listing notice — Nasdaq notifies Phoenix Biotech of MVLS non-compliance for 30 consecutive days

CERO THERAPEUTICS HOLDINGS, INC.

Received Nasdaq letter on April 3, 2023; common stock MVLS below $50M minimum for 30 consecutive trading days.
Has 180 days (until October 2, 2023) to regain compliance under Listing Rule 5810(c)(3)(C).
To regain compliance, MVLS must close at or above $50M for at least ten consecutive business days.
If not compliant by deadline, may transfer to Nasdaq Capital Market or face delisting with appeal rights.
Deficiency notice has no immediate effect on listing or trading; Company monitoring options.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

April 3, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), received a letter (the “ Letter ”) from the staff at The Nasdaq Global Market (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-028305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.